FRANKFURT (Dow Jones)–Reluctance characterized after-hours trading on Tuesday. Among the individual stocks, Morphosys stood out, rising by almost 4 percent in the evening. The US Food and Drug Administration (FDA) has granted Fast Track designation to Morphosys’ drug tulmimetostat for the treatment of uterine cancer. This is intended to facilitate and accelerate the development and testing of active ingredients that could be used to potentially treat serious diseases or cover unmet medical needs, as Morphosys announced.
===
XDAX* DAX change
10:15 p.m. 5:30 p.m
15,708 15,716 -0.1%
===
*The XDAX reflects the development of the interest-adjusted DAX futures.
Contact the author: [email protected]
DJG/cln
(END) Dow Jones Newswires
September 12, 2023 4:28 p.m. ET (8:28 p.m. GMT)
Selected leveraged products on MorphoSys
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on MorphoSys
The leverage must be between 2 and 20